Maze Therapeutics, Inc. MAZE
32.43 USD +1.23 (+3.94%)
Regular-session close
32.46 +0.03 +0.09%
After hours · Nov 19, 7:43 PM ET
30.69 Day range 32.74
21.95 52-week range 53.65
- YTD
- -21.72%
- 1 year
- -8.75%
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 62.46 +92.6% upside
Now 32.43
- Target (low)
- 46.00
- Target (mean)
- 62.46
- Target (high)
- 110.00
Ratings (0m) 14 14 buy · 0 hold · 0 sell
- Strong buy1
- Buy13
- Hold0
- Sell0
- Strong sell0
Recommendation trend
- This month 14
- 1 month ago 14
- 2 months ago 13
- 3 months ago 12
Included in Essentials and up
Sign in to see Revenue and earnings forecast
Reported revenue and earnings per share by year, then what analysts expect next.
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.7518 | -0.87172 – -0.56 | -0.65 | -15.7% | 0 | 0.0% | 10 |
| Next quarter | -0.79143 | -0.93533 – -0.59 | -0.65 | -21.8% | 2.26M | -88.7% | 8 |
| Current year | -2.86 | -2.95 – -2.68 | -3.05 | +6.1% | 20.00M | 0.0% | 8 |
| Next year | -3.30 | -4.36 – -2.31 | -2.86 | -15.2% | 8.11M | -59.5% | 11 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 11, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Nov 10, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Oct 19, 2026 | Canaccord Genuity | Initiated | — | Buy |
| Sep 24, 2026 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 23, 2026 | Citigroup | Initiated | — | Buy |
| Sep 23, 2026 | Wedbush | Reiterated | Outperform | Outperform |
| Sep 22, 2026 | BTIG | Reiterated | Buy | Buy |
| Aug 12, 2026 | BTIG | Reiterated | Buy | Buy |
| Apr 14, 2026 | Truist Securities | Maintained | Buy | Buy |
| Mar 31, 2026 | JP Morgan | Maintained | Overweight | Overweight |
| Mar 25, 2026 | BTIG | Reiterated | Buy | Buy |
| Mar 25, 2026 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Mar 18, 2026 | Truist Securities | Initiated | — | Buy |
| Mar 16, 2026 | Wedbush | Maintained | Outperform | Outperform |
| Mar 10, 2026 | Mizuho | Initiated | — | Outperform |
| Mar 9, 2026 | BTIG | Reiterated | Buy | Buy |
| Mar 4, 2026 | Guggenheim | Maintained | Buy | Buy |
| Jan 16, 2026 | BTIG | Maintained | Buy | Buy |
| Dec 4, 2025 | Wells Fargo | Initiated | — | Overweight |
| Dec 3, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Nov 7, 2025 | Wedbush | Maintained | Outperform | Outperform |
| Sep 29, 2025 | JP Morgan | Maintained | Overweight | Overweight |
| Sep 18, 2025 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Sep 15, 2025 | Guggenheim | Maintained | Buy | Buy |
| Sep 12, 2025 | HC Wainwright & Co. | Maintained | Buy | Buy |
| Sep 12, 2025 | BTIG | Maintained | Buy | Buy |
| Sep 11, 2025 | BTIG | Maintained | Buy | Buy |
| Sep 2, 2025 | BTIG | Initiated | — | Buy |
| Jul 23, 2025 | HC Wainwright & Co. | Initiated | — | Buy |
| Jul 8, 2025 | Wedbush | Initiated | — | Outperform |
Included in Plus and up
Sign in to see Analyst trend
Two years of the analyst rating mix and the average price target against the price.
